Trials / Completed
CompletedNCT02064439
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 3,365 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, randomized, double-blind, event-driven, superiority study for efficacy. Patients with confirmed symptomatic DVT (Deep Vein Thrombosis) or PE (Pulmonary embolism) who completed 6 or 12 months of treatment of anticoagulation are eligible for this trial
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BAY 59-7939 | 10 mg tablet once daily for 12 months |
| DRUG | BAY 59-7939 | 20 mg tablet once daily for 12 months |
| DRUG | ASA | 100 mg tablet once daily for 12 months |
Timeline
- Start date
- 2014-03-05
- Primary completion
- 2016-09-22
- Completion
- 2016-11-04
- First posted
- 2014-02-17
- Last updated
- 2017-12-19
- Results posted
- 2017-12-19
Locations
266 sites across 31 countries: United States, Australia, Austria, Belgium, Brazil, Canada, China, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Mexico, Netherlands, New Zealand, Norway, Philippines, Poland, Russia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey (Türkiye), United Kingdom, Vietnam
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02064439. Inclusion in this directory is not an endorsement.